Ipca Laboratories Ltd
Ipca Laboratories Ltd Share Price Today: Live Updates & Key Insights
Get insights on Ipca Laboratories Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Ipca Laboratories Ltd Share Price Chart
Ipca Laboratories Ltd Fundamentals
Traded Volume: 1,74,552
Market Cap(Cr): 36,635
Avg Traded Price 1443.13
1 Year return -8.23%
Upper Circuit 1,455.5
Lower Circuit 1,426.9
P/E TTM 44.00
P/B Ratio 33.00
Traded Value(Cr) 2520.53
EPS TTM 32.784
Book value 32.784
Dividend 0.00%
Ipca Laboratories Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Ipca Laboratories Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Ipca Laboratories Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W +10.91%
1M +13.61%
3M +5.37%
1Y -8.23%
YTD -15.05%
Ipca Laboratories Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Ipca Laboratories Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 1.66L
Day Before Yesterday 3.27L
1W Avg 12.27L
1M Avg 4.08L
3M Avg 2.59L
Ipca Laboratories Ltd Technical Details
Ipca Laboratories Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 1429
Support 2 1414
Support 3 1400
Pivot Point : 1442
Resistance 1 1457
Resistance 2 1471
Resistance 3 1486
Ipca Laboratories Ltd Corporate Actions
Ipca Laboratories Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Ipca Laboratories Ltd’s capital allocation strategies.
All
Ex-Date 05-Aug-2025 Type D Description 2.00/share@200.00% Record Date 05-Aug-2025 Ratio 200.00
Ex-Date 27-Nov-2024 Type D Description 2.00/share@200.00% Record Date 27-Nov-2024 Ratio 200.00
Ex-Date 06-Aug-2024 Type D Description 2.00/share@200.00% Record Date - Ratio 200.00
Ex-Date 22-Nov-2023 Type D Description 2.00/share@200.00% Record Date 22-Nov-2023 Ratio 200.00
Ex-Date 22-Nov-2022 Type D Description 4.00/share@400.00% Record Date 23-Nov-2022 Ratio 400.00
Ex-Date 10-Jan-2022 Type S Description share@1:2.00 Record Date 11-Jan-2022 Ratio 1:2.00
Ex-Date 22-Nov-2021 Type D Description 8.00/share@400.00% Record Date 23-Nov-2021 Ratio 400.00
Ex-Date 13-Nov-2020 Type D Description 8.00/share@400.00% Record Date 17-Nov-2020 Ratio 400.00
Ex-Date 18-Feb-2020 Type D Description 5.00/share@250.00% Record Date 20-Feb-2020 Ratio 250.00
Ex-Date 06-Aug-2019 Type D Description 3.00/share@150.00% Record Date - Ratio 150.00
Ex-Date 02-Aug-2018 Type D Description 1.00/share@50.00% Record Date - Ratio 50.00
Ex-Date 27-Jul-2017 Type D Description 1.00/share@50.00% Record Date - Ratio 50.00
Ex-Date 22-Jul-2015 Type D Description 1.00/share@50.00% Record Date - Ratio 50.00
Ex-Date 18-Jul-2014 Type D Description 2.50/share@125.00% Record Date - Ratio 125.00
Ex-Date 31-Oct-2013 Type D Description 2.50/share@125.00% Record Date 01-Nov-2013 Ratio 125.00
Ex-Date 19-Jul-2013 Type D Description 2.00/share@100.00% Record Date - Ratio 100.00
Ex-Date 01-Nov-2012 Type D Description 2.00/share@100.00% Record Date 02-Nov-2012 Ratio 100.00
Ex-Date 20-Jul-2012 Type D Description 1.20/share@60.00% Record Date - Ratio 60.00
Ex-Date 07-Feb-2012 Type D Description 1.00/share@50.00% Record Date 08-Feb-2012 Ratio 50.00
Ex-Date 03-Nov-2011 Type D Description 1.00/share@50.00% Record Date 07-Nov-2011 Ratio 50.00
Ex-Date 18-Jul-2011 Type D Description 1.20/share@60.00% Record Date - Ratio 60.00
Ex-Date 01-Feb-2011 Type D Description 1.00/share@50.00% Record Date 02-Feb-2011 Ratio 50.00
Ex-Date 28-Oct-2010 Type D Description 1.00/share@50.00% Record Date 29-Oct-2010 Ratio 50.00
Ex-Date 16-Jul-2010 Type D Description 1.00/share@50.00% Record Date - Ratio 50.00
Ex-Date 22-Mar-2010 Type S Description share@1:5.00 Record Date 23-Mar-2010 Ratio 1:5.00
Ex-Date 27-Jan-2010 Type D Description 4.00/share@40.00% Record Date 28-Jan-2010 Ratio 40.00
Ex-Date 30-Oct-2009 Type D Description 5.00/share@50.00% Record Date 03-Nov-2009 Ratio 50.00
Ex-Date 20-Jul-2009 Type D Description 4.00/share@40.00% Record Date - Ratio 40.00
Ex-Date 27-Jan-2009 Type D Description 3.00/share@30.00% Record Date 28-Jan-2009 Ratio 30.00
Ex-Date 07-Nov-2008 Type D Description 4.00/share@40.00% Record Date 10-Nov-2008 Ratio 40.00
Ex-Date 14-Jul-2008 Type D Description 4.50/share@45.00% Record Date - Ratio 45.00
Ex-Date 06-Nov-2007 Type D Description 3.50/share@35.00% Record Date 07-Nov-2007 Ratio 35.00
Ex-Date 10-Jul-2007 Type D Description 4.00/share@40.00% Record Date - Ratio 40.00
Dividends
Announcement Date 05-Aug-2025 Ex Dividend Date 05-Aug-2025 Dividend(%) 200
Announcement Date 27-Nov-2024 Ex Dividend Date 27-Nov-2024 Dividend(%) 200
Announcement Date 06-Aug-2024 Ex Dividend Date 06-Aug-2024 Dividend(%) 200
Announcement Date 22-Nov-2023 Ex Dividend Date 22-Nov-2023 Dividend(%) 200
Announcement Date 22-Nov-2022 Ex Dividend Date 22-Nov-2022 Dividend(%) 400
Announcement Date 22-Nov-2021 Ex Dividend Date 22-Nov-2021 Dividend(%) 400
Announcement Date 13-Nov-2020 Ex Dividend Date 13-Nov-2020 Dividend(%) 400
Announcement Date 18-Feb-2020 Ex Dividend Date 18-Feb-2020 Dividend(%) 250
Announcement Date 06-Aug-2019 Ex Dividend Date 06-Aug-2019 Dividend(%) 150
Announcement Date 02-Aug-2018 Ex Dividend Date 02-Aug-2018 Dividend(%) 50
Announcement Date 27-Jul-2017 Ex Dividend Date 27-Jul-2017 Dividend(%) 50
Announcement Date 22-Jul-2015 Ex Dividend Date 22-Jul-2015 Dividend(%) 50
Announcement Date 18-Jul-2014 Ex Dividend Date 18-Jul-2014 Dividend(%) 125
Announcement Date 31-Oct-2013 Ex Dividend Date 31-Oct-2013 Dividend(%) 125
Announcement Date 19-Jul-2013 Ex Dividend Date 19-Jul-2013 Dividend(%) 100
Announcement Date 01-Nov-2012 Ex Dividend Date 01-Nov-2012 Dividend(%) 100
Announcement Date 20-Jul-2012 Ex Dividend Date 20-Jul-2012 Dividend(%) 60
Announcement Date 07-Feb-2012 Ex Dividend Date 07-Feb-2012 Dividend(%) 50
Announcement Date 03-Nov-2011 Ex Dividend Date 03-Nov-2011 Dividend(%) 50
Announcement Date 18-Jul-2011 Ex Dividend Date 18-Jul-2011 Dividend(%) 60
Announcement Date 01-Feb-2011 Ex Dividend Date 01-Feb-2011 Dividend(%) 50
Announcement Date 28-Oct-2010 Ex Dividend Date 28-Oct-2010 Dividend(%) 50
Announcement Date 16-Jul-2010 Ex Dividend Date 16-Jul-2010 Dividend(%) 50
Announcement Date 27-Jan-2010 Ex Dividend Date 27-Jan-2010 Dividend(%) 40
Announcement Date 30-Oct-2009 Ex Dividend Date 30-Oct-2009 Dividend(%) 50
Announcement Date 20-Jul-2009 Ex Dividend Date 20-Jul-2009 Dividend(%) 40
Announcement Date 27-Jan-2009 Ex Dividend Date 27-Jan-2009 Dividend(%) 30
Announcement Date 07-Nov-2008 Ex Dividend Date 07-Nov-2008 Dividend(%) 40
Announcement Date 14-Jul-2008 Ex Dividend Date 14-Jul-2008 Dividend(%) 45
Announcement Date 06-Nov-2007 Ex Dividend Date 06-Nov-2007 Dividend(%) 35
Announcement Date 10-Jul-2007 Ex Dividend Date 10-Jul-2007 Dividend(%) 40
Bonus
No Bonus has been declared by IPCALAB
Splits
Record Date 11-Jan-2022 Split Date 10-Jan-2022 Face Value (Before/After) 2.00/1.00
Record Date 23-Mar-2010 Split Date 22-Mar-2010 Face Value (Before/After) 10.00/2.00
Others
Rights No Rights has been declared by IPCALAB
Ipca Laboratories Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Ipca Laboratories Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Ipca Laboratories Ltd's relative performance and valuation against major competitors.
Stock Name Laurus Labs Ltd ₹978.20 (-0.90%) M. Cap (Cr) 528.06 1 Yr Return (%) +99.98% P/E (TTM) 77.21 PB Ratio 11.81
Stock Name Glenmark Pharmaceuticals Ltd ₹1844.20 (-1.80%) M. Cap (Cr) 520.43 1 Yr Return (%) +25.76% P/E (TTM) 51.54 PB Ratio 5.88
Stock Name Glaxosmithkline Pharmaceuticals Ltd ₹2497.90 (-0.44%) M. Cap (Cr) 423.16 1 Yr Return (%) +5.41% P/E (TTM) 44.30 PB Ratio 21.69
Stock Name Ipca Laboratories Ltd ₹1444.00 (+0.40%) M. Cap (Cr) 366.35 1 Yr Return (%) -8.23% P/E (TTM) 44.05 PB Ratio 5.27
Stock Name Anthem Biosciences Ltd ₹635.10 (-1.91%) M. Cap (Cr) 356.68 1 Yr Return (%) NaN% P/E (TTM) 69.10 PB Ratio 14.80
Stock Name Ajanta Pharma Ltd ₹2485.70 (-1.00%) M. Cap (Cr) 310.55 1 Yr Return (%) -15.61% P/E (TTM) 31.89 PB Ratio 8.44
Stock Name Gland Pharma Ltd ₹1809.70 (-0.42%) M. Cap (Cr) 298.16 1 Yr Return (%) +1.27% P/E (TTM) 37.72 PB Ratio 3.26
Ipca Laboratories Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Ipca Laboratories Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 1374.07 Mar 2024 830.51 Mar 2023 762.29 Mar 2022 840.14 Mar 2021 1096.06
PARTICULARS Investing Activities Mar 2025 -738.81 Mar 2024 -1355.18 Mar 2023 -709.61 Mar 2022 -823.89 Mar 2021 -559.56
PARTICULARS Financing Activities Mar 2025 -428.44 Mar 2024 -464.88 Mar 2023 506.38 Mar 2022 426.10 Mar 2021 -307.38
PARTICULARS Net Cash Flow Mar 2025 206.82 Mar 2024 -989.55 Mar 2023 559.06 Mar 2022 442.35 Mar 2021 229.12
Ipca Laboratories Ltd Shareholding Pattern
This shows the ownership breakdown of Ipca Laboratories Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 44.72%
Public 8.09%
Other Institutions 6.73%
FII 10.42%
Mutual Funds 30.04%
About Ipca Laboratories Ltd
Ipca Laboratories Limited (IPCA) was incorporated on 19 October, 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 API's covering various therapeutic segments. The products of the Company are now sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing API's and formulations for the world market.Ipca's APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries. Ipca is one of the biggest manufacturers in the world of APIs Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic) right from the basic stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over. The name of the company was changed to `Ipca Laboratories Limited' in 6th August of the year 1964 and again name was changed to `Ipca Laboratories Private Limited' in 13th January of the year 1966. Ipca had commissioned one of the first modern Pharma factory of yesteryears in the year 1969 at Mumbai. The present management took over the company in November of the year 1975. In the year 1976, started domestic marketing operations, the first company to offer sugarcoated Chloroquine tablets. Launched formulations of Metoclopramide under brand name 'Perinorm' for the first time in India during the year 1978. After two years, in 1980, the company had launched formulations of Bromhexine for the first time in India. Ipca's first APIs plant was commissioned at Ratlam in the year 1984 and also in the same period the second formulations plant was commissioned at Ratlam itself. Ipca's first APIs Plant for manufacturing of Chloroquine Phosphate was set up at Ratlam in the year 1986. As at 9th August 1988, again the company had changed its name to `Ipca Laboratories Limited'. Ipca's status was converted to a Public Limited Company in 24th March of the year 1993 and also in the same year, the company had acquired Hoechst India's formulations unit at Kandla.During the year 1994, Ipca had acquired API Plant from BDH Pharmaceuticals (a subsidiary of E. Merck) at Indore. In the year 1995, the modern formulations plant at Athal (Silvassa) came to line. After a year, in 1996, the company had commissioned new API R&D Centre at Mumbai. In 2000, received ISO 9001 certification for Athal Plant. The Company had incorporated two subsidiaries in Mauritius in the year of 2001 under the name of Solway Investments Ltd and 'Sundridge Management Ltd. during the year 2002, launched new domestic marketing division, Intima to promote established brands with a focus on micro-interior marketing and also in the same year incorporated wholly owned subsidiary in Brazil under the name of Laboratories Ipca Do Brasil Ltd. Launched new domestic marketing division in the year 2003 as Activa, dedicated to Rheumatology Care. Forbes, a leading US business magazine, selected among its top 200 successful, rising companies outside USA in the same year 2003. Commissioned new formulation plant at Silvassa in the year 2004. Forbes selected Ipca, for the second consecutive year as one among the first 200 'Best under a Billion Company' in Asia. Innotech Pharma Limited was merged with Ipca in August of the year 2005. During the same year, Ipca entered in to Joint Venture with Holley Group of China for marketing Artemisinin based API and Formulation. Joint Venture setup in SAIF Zone, Sharjah, U.A.E. and named as ACTIVA Pharmaceuticals FZC. Also acquired Cardiac brand ISORDIL from Wyeth Limited. Ipca had entered into strategic alliance with Ranbaxy Pharmaceuticals Inc. for the U.S market in the year 2006. The Company's new plant at Dehradun was commenced operation from 5th May of the year 2006. As of January 2007, Ipca and Ranbaxy alliance had received U.S. FDA marketing approval for Atenolol Tablets. Ipca's New Biotech Research & Development Unit was inaugurated at Mumbai in March of the same year 2007. Ipca had awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2007. Ipca had received final approval from the US FDA, for Metoclopramide tablets in June 2008. The Company had signed a partnership agreement with Clinton Foundation in July of the same year 2008. The Company plans to develop various APIs/intermediates having good potential for exports and local market. It plans additional investment in manpower, latest instrumentation to upgrade and strengthen R&D facilities. Also, the company aims at developing newer drug delivery systems along with developing formulations for developed market and bio-equivalence studies of the same.During the FY 2015, the Company acquired assets of formulations manufacturing unit situated at Plot No. T-139, MIDC,Tarapur, Palghar - 401506. The Company has also acquired as a going concern on slump sale basis the High Potency (Hormonal) Oral Solid Dosage formulations manufacturing unit situated at Sector III, Pithampur, Dhar (Madhya Pradesh) together with its employees. This manufacturing unit has the approval of WHO-GMP, INVIMA Colombia and German.During the year 2015, the Company acquired joint management stake in M/s. Krebs Biochemicals & Industries Ltd., a listed public limited company with fermentation based APIs manufacturing facilities situated at Visakhapatnam and Nellore (Andhra Pradesh). The Company had also made public announcement of open offer to the public shareholders of the said company under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.M/s. Krebs Biochemicals and Industries Ltd. became an associate company. No other company has become / ceased to be subsidiary or joint venture or associate company during the financial year 2015.During the year, as a part of group re-construction, Ipca Laboratories (UK) Ltd. acquired the entire issued share capital of Onyx Scientific Ltd., UK from its wholly owned subsidiary, Onyx Research Chemicals Ltd., U.K. on 25th March, 2015 in lieu of capital dividend declared by the said company. Consequent to this, Onyx Scientific Ltd., UK has become wholly owned subsidiary of Ipca Laboratories (UK) Ltd. from the said date. From the said date, Onyx Research Chemicals Ltd. UK has ceased to trade and is in the process of being dissolved. The wholly owned subsidiary company, Ipca Pharmaceuticals (Shanghai) Ltd., incorporated in the Peoples Republic of China, is in the process of being voluntarily closed down.During the year 2016, the wholly owned subsidiary companies, Ipca Pharmaceuticals (Shanghai) Ltd. incorporated in the People's Republic of China and National Druggists Pty Ltd. incorporated in the Republic of South Africa were voluntarily closed down. Onyx Research Chemicals Limited, U.K. merged with its holding company Ipca Laboratories (UK) Ltd. Consequent to this, Onyx Scientific Ltd. has now become wholly owned subsidiary of Ipca Laboratories (U.K.) Ltd. which in turn is the wholly owned subsidiary of the Company.During the year 2018, the Company acquired 100% share capital of Pisgah Labs Inc. a North Carolina Corporation, Old Hendersonville Highway, Pisgah Forest, North Carolina, USA through Ipca Pharmaceutical Inc., USA (Company's wholly owned subsidiary) and Onyx Scientific Ltd., U.K (Onyx) (Company's wholly owned step down subsidiary) for US$ 9.65 millions, free of debt. Pisgah was founded as a contract manufacturer and developer of active pharmaceutical ingredients (APIs) and intermediates. During the year 2019-20, the Company acquired 100% paid-up share capital of M/s. Ramdev Chemical Private Limited on 24th April, 2019 and became its wholly owned subsidiary.During the year 2021, M/s. Trophic Wellness Private Ltd., got incorporated with the Company and became its subsidiary.During year 2022, Company acquired 26.57% of share capital of M/s. Lyka Labs Limited with the Promoters of the said Company. It made a Public Offer to acquire additional 26% Equity Shares of the said Company from its public shareholders, where the Company now holds 26.58% of the equity share capital of the said Company.During the financial year 2022-23, the Company acquired further 6.53% of the paid-up equity share capital of Trophic Wellness Private Ltd. With this acquisition, the Company holds 58.88% of the paid-up equity share capital of the said Company. During the financial year 2022-23, the Company acquired, thru preferential allotment, further 4.78% of the paid-up equity share capital of Lyka Labs Ltd. Also, in the month of April, 2023, the Company acquired another 4.98% of the paid-up share capital of the said company thru part conversion of warrants issued on preferential basis. With these share allotments, the Company now holds 36.34% of the paid-up equity share capital of Lyka Labs Ltd.During 2022-23, the merger of M/s. Ramdev Chemical Pvt. Ltd. and M/s. Tonira Exports Ltd., Company's wholly owned subsidiaries with the Company was effective from 1st April, 2022.The Company's Active Pharmaceuticals Ingredients (APIs) at Dewas (Madhya Pradesh) commenced trial production in September, 2022.In 2024-25, e Company acquired 100% of the paid-up equity share capital of Unichem Laboratories Ltd, Ireland, a wholly owned subsidiary of company's subsidiary, making Unichem Labs, Ireland a wholly owned subsidiary of the Company.
Chairman / Executive Director / M D / Promoter
Premchand Godha
Registered office 48 Kandivli Industrial Estate, Kandivli (West), Mumbai, Maharashtra, 400067
FAX :91-22-66474444
Background
Incorporation Year 1949
Face Value ₹1.00
Market Lot 1
FAQs on Ipca Laboratories Ltd
How to buy Ipca Laboratories Ltd shares on NSE?
To buy Ipca Laboratories Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Ipca Laboratories Ltd share price today?
The Ipca Laboratories Ltd share price on NSE is ₹1444.00 today.
What is the market cap of Ipca Laboratories Ltd on NSE?
The company has a market capitalization of ₹36634.89.
What is the PE & PB ratio of Ipca Laboratories Ltd?
PE is 44 and PB is 33.
What is the 52 Week High and Low of Ipca Laboratories Ltd shares?
Ipca Laboratories Ltd stock price high: ₹1755.90 Ipca Laboratories Ltd stock price low: ₹1168.20.
Is Ipca Labs a government-run institution?
No, IPCA Laboratories is not a government-run organization. It is a privately-owned pharmaceutical company based in India. IPCA Laboratories was founded in 1949 and has since grown to become one of the leading pharmaceutical companies in India.
Who is Ipca Labs’ owner?
IPCA Laboratories is a publicly-traded company and its ownership is spread among its shareholders. The Promoter of IPCA Labs is Mr. Premchand Godha and his family.
How well is Ipca Labs doing?
IPCA Laboratories operates in the pharmaceutical industry and has a diverse product portfolio that includes medicines for various therapeutic segments, including antimalarials, anti-bacterial, pain management, and cardiovascular drugs.
What are the latest results of Ipca Labs?
The last fiscal result of Ipca Labs was declared in March 2022 and they reported a consolidated revenue of INR 5,829.79 crore and net profit of Rs. 910.95 crores.
What are the potential catalysts that positively impact the stock price of Ipca lab?
Some potential catalysts that may positively affect IPCA Laboratories' stock price could include: